Abstract
Host development of human anti-mouse antibodies (HAMA) in response to administered antibodies has been reported as a problem for antibody imaging and therapy However; radioimmunotherapy has been shown to be effective in patients with B-cell malignancies because their immunodeficient state precludes or delays development of a HAMA response to mouse antibodies. Baseline HAMA activity was assayed in 60 patients with B-lymphocytic non-Hodgkin's lymphoma or chronic lymphocytic leukemia and sequentially in 43 patients who were subsequently treated with radiolabeled Lym-1 antibody. Pre-existing 'HAMA' activity was found in 3 (5%) of the 60 patients screened for treatment consideration. The incidence of development of HAMA in the 43 patients treated with multiple doses of radiolabebed Lym-1 antibody was 12 (28%). There was no evidence for an anaphylactoid or related response in the HAMA positive patients. HAMA activity interrupted therapy in 14% of the patients (6 of 43) but did not preclude therapeutic responses to radiolabeled Lym-1 therapy. Median survival for the HAMA positive patients was longer (18 months) than for those who did not develop HAMA activity (9 months).
| Original language | English (US) |
|---|---|
| Pages (from-to) | 67-74 |
| Number of pages | 8 |
| Journal | International Journal of Biological Markers |
| Volume | 10 |
| Issue number | 2 |
| State | Published - 1995 |
Fingerprint
Keywords
- Antiglobulin
- Chronic lymphocytic leukemia
- HAMA
- Lym-1
- Lymphoma
- Radioimmunotherapy
ASJC Scopus subject areas
- Immunology
- Biochemistry
Cite this
Analysis of antiglobulin (HAMA) response in a group of patients with B-lympkocytic malignancies treated with 131I-Lym-1. / Denardo, Gerald L; Kroger, L. A.; Mirick, G. R.; Lamborn, K. R.; De Nardo, S. J.
In: International Journal of Biological Markers, Vol. 10, No. 2, 1995, p. 67-74.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Analysis of antiglobulin (HAMA) response in a group of patients with B-lympkocytic malignancies treated with 131I-Lym-1
AU - Denardo, Gerald L
AU - Kroger, L. A.
AU - Mirick, G. R.
AU - Lamborn, K. R.
AU - De Nardo, S. J.
PY - 1995
Y1 - 1995
N2 - Host development of human anti-mouse antibodies (HAMA) in response to administered antibodies has been reported as a problem for antibody imaging and therapy However; radioimmunotherapy has been shown to be effective in patients with B-cell malignancies because their immunodeficient state precludes or delays development of a HAMA response to mouse antibodies. Baseline HAMA activity was assayed in 60 patients with B-lymphocytic non-Hodgkin's lymphoma or chronic lymphocytic leukemia and sequentially in 43 patients who were subsequently treated with radiolabeled Lym-1 antibody. Pre-existing 'HAMA' activity was found in 3 (5%) of the 60 patients screened for treatment consideration. The incidence of development of HAMA in the 43 patients treated with multiple doses of radiolabebed Lym-1 antibody was 12 (28%). There was no evidence for an anaphylactoid or related response in the HAMA positive patients. HAMA activity interrupted therapy in 14% of the patients (6 of 43) but did not preclude therapeutic responses to radiolabeled Lym-1 therapy. Median survival for the HAMA positive patients was longer (18 months) than for those who did not develop HAMA activity (9 months).
AB - Host development of human anti-mouse antibodies (HAMA) in response to administered antibodies has been reported as a problem for antibody imaging and therapy However; radioimmunotherapy has been shown to be effective in patients with B-cell malignancies because their immunodeficient state precludes or delays development of a HAMA response to mouse antibodies. Baseline HAMA activity was assayed in 60 patients with B-lymphocytic non-Hodgkin's lymphoma or chronic lymphocytic leukemia and sequentially in 43 patients who were subsequently treated with radiolabeled Lym-1 antibody. Pre-existing 'HAMA' activity was found in 3 (5%) of the 60 patients screened for treatment consideration. The incidence of development of HAMA in the 43 patients treated with multiple doses of radiolabebed Lym-1 antibody was 12 (28%). There was no evidence for an anaphylactoid or related response in the HAMA positive patients. HAMA activity interrupted therapy in 14% of the patients (6 of 43) but did not preclude therapeutic responses to radiolabeled Lym-1 therapy. Median survival for the HAMA positive patients was longer (18 months) than for those who did not develop HAMA activity (9 months).
KW - Antiglobulin
KW - Chronic lymphocytic leukemia
KW - HAMA
KW - Lym-1
KW - Lymphoma
KW - Radioimmunotherapy
UR - http://www.scopus.com/inward/record.url?scp=0029010764&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029010764&partnerID=8YFLogxK
M3 - Article
C2 - 7561241
AN - SCOPUS:0029010764
VL - 10
SP - 67
EP - 74
JO - International Journal of Biological Markers
JF - International Journal of Biological Markers
SN - 0393-6155
IS - 2
ER -